Linked Data API

Show Search Form

Search Results

1128943
star this property registered interest false more like this
star this property date less than 2019-06-03more like thismore than 2019-06-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care remove filter
star this property hansard heading Cancer Drugs Fund more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Cancer Drugs Fund in meeting the needs of people with rarer and less common cancers. more like this
star this property tabling member constituency Crawley more like this
star this property tabling member printed
Henry Smith remove filter
star this property uin 259175 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-06-11more like thismore than 2019-06-11
star this property answer text <p>Following the reforms to the Cancer Drugs Fund (CDF) in July 2016 all new cancer drugs and significant new licensed indications for existing drugs are referred to the National Institute for Health and Care Excellence (NICE). This included the referral of all licensed cancer drug indications for rare cancers that had not previously been assessed by NICE.</p><p>This has led to an increase in the number, and proportion, of NICE appraisals of treatments for rare cancers. Since July 2016 21% or 24 out of 114 cancer drugs appraised by NICE have been for rarer cancers, compared to 9% or 18 out of 200, before the CDF reforms. Of these 24 drugs for rare cancers, 22 have been recommended for routine commissioning and two for use within the CDF. This shows that changes to the appraisal and funding of cancer drugs has led to an increase in the number of treatments for rare cancers both assessed by NICE and funded by NHS England in routine commissioning and via the CDF.</p><p> </p><p><strong> </strong></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
remove filter
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
3960
unstar this property label Biography information for Henry Smith more like this